SynthesisFrontiers in neurology2025
The levels of miR-155 in epilepsy patients: a meta-analysis.
Synthesis in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MiRNA Dysregulation in Epilepsy: Bridging Molecular Mechanisms and Therapeutic Innovation.Molecular neurobiology · 2026Review
- Markers of Antiseizure Treatment Efficacy in Children: A Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuroinflammation plays an important role in the development and progression of epilepsy. It can be both a result and a potential cause of those seizures. MiR-155 plays a crucial role in inflammatory responses, and its expression is upregulated under various neuroinflammatory conditions. This study aims to compare the expression levels of miR-155 in the brain tissue or serum of epilepsy patients and healthy controls, assessing the correlation between miR-155 levels and epilepsy. Objective: The meta-analysis evaluates to assess and compare the levels of miR-155 in the brain tissue and serum of epilepsy patients and healthy controls. Methods: The databases PubMed, Embase, Cochrane Library, CNKI, VIP, and WanFang DATA were searched from inception until Dec 30, 2024 by two researchers. The relative expression level of miR-155 in the tissues or serum was the primary outcome of the search. After extracting data independently, the two researchers used the Cochrane Collaboration's tool for assessing risk of bias. All data were analyzed using Review Manager (V.5.4.1) statistical software. Results: This meta-analysis (nine studies, 394 patients) reveals elevated miR-155 in epilepsy patients vs. controls (SMD = 1.62, Conclusion: Compared to healthy controls, the relative expression level of miR-155 in the brain tissue or serum of epilepsy patients increased. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier: CRD42024558255.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.